2Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005, 23(5 ) : 479-490.
3Vermeire S, Van-Assche G, Rutgeerts P, et al. Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. Curt Opin Gastroentero1,2011,27 ( 1 ) :32-37.
4Seidelin JB, Rogler G, Nielsen OH. A role for interleukin-33 in T (H) 2-polarized intestinal inflammation. Mueosal Immunol, 2011, 4 ( 5 ) :496-502.
5Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-l-like cyto- kine ligand for ST2 receptor, is a chromatin-associated nuclear fac- tor in vivo. Proc Natl Acad Sci USA, 2007, 104 ( 1 ) : 282-287.
6Sponheim J, Pollheimer J, Olsen T, et al. Inflammatory bowel disease-assoeiated interleukin-33 is preferentially expressed in ul- ceration-associated myofibroblasts. Am J Pathol, 2010 , 177 (6) : 2804-2815.
7Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroentero1,2010,45 (10) : 999-1007.
8Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem,2007,282 ( 36 ) : 26369-26380.
9Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor ac- cessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cyto- kine, 2008, 42 (3) : 358-364.
10Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol, 2011,7 (6) :321-329.
